382 related articles for article (PubMed ID: 22467215)
1. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.
Thiel KW; Hernandez LI; Dassie JP; Thiel WH; Liu X; Stockdale KR; Rothman AM; Hernandez FJ; McNamara JO; Giangrande PH
Nucleic Acids Res; 2012 Jul; 40(13):6319-37. PubMed ID: 22467215
[TBL] [Abstract][Full Text] [Related]
2. Systemic Delivery of Aptamer-Conjugated XBP1 siRNA Nanoparticles for Efficient Suppression of HER2+ Breast Cancer.
Zhang L; Mu C; Zhang T; Wang Y; Wang Y; Fan L; Liu C; Chen H; Shen J; Wei K; Li H
ACS Appl Mater Interfaces; 2020 Jul; 12(29):32360-32371. PubMed ID: 32613835
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.
Xue L; Maihle NJ; Yu X; Tang SC; Liu HY
Mol Pharm; 2018 Nov; 15(11):4801-4813. PubMed ID: 30222359
[TBL] [Abstract][Full Text] [Related]
4. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
[TBL] [Abstract][Full Text] [Related]
5. Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells.
Thiel WH; Thiel KW; Flenker KS; Bair T; Dupuy AJ; McNamara JO; Miller FJ; Giangrande PH
Methods Mol Biol; 2015; 1218():187-99. PubMed ID: 25319652
[TBL] [Abstract][Full Text] [Related]
6. Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.
Saatci Ö; Borgoni S; Akbulut Ö; Durmuş S; Raza U; Eyüpoğlu E; Alkan C; Akyol A; Kütük Ö; Wiemann S; Şahin Ö
Oncogene; 2018 Apr; 37(17):2251-2269. PubMed ID: 29391599
[TBL] [Abstract][Full Text] [Related]
7. Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX.
Dastjerdi K; Tabar GH; Dehghani H; Haghparast A
Biotechnol Appl Biochem; 2011; 58(4):226-30. PubMed ID: 21838796
[TBL] [Abstract][Full Text] [Related]
8. Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery.
Zhou J; Li H; Zhang J; Piotr S; Rossi J
J Vis Exp; 2011 Jun; (52):. PubMed ID: 21730942
[TBL] [Abstract][Full Text] [Related]
9. [Advance in the study of targeting delivery system for siRNA mediated by aptamers].
Wang XL; Wang QQ; Song HF
Yao Xue Xue Bao; 2012 Jul; 47(7):850-5. PubMed ID: 22993847
[TBL] [Abstract][Full Text] [Related]
10. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth.
Mahlknecht G; Maron R; Mancini M; Schechter B; Sela M; Yarden Y
Proc Natl Acad Sci U S A; 2013 May; 110(20):8170-5. PubMed ID: 23630281
[TBL] [Abstract][Full Text] [Related]
11. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
12. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A
PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311
[TBL] [Abstract][Full Text] [Related]
13. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis.
Yao YD; Sun TM; Huang SY; Dou S; Lin L; Chen JN; Ruan JB; Mao CQ; Yu FY; Zeng MS; Zang JY; Liu Q; Su FX; Zhang P; Lieberman J; Wang J; Song E
Sci Transl Med; 2012 Apr; 4(130):130ra48. PubMed ID: 22517885
[TBL] [Abstract][Full Text] [Related]
15. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
[TBL] [Abstract][Full Text] [Related]
16. Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells.
Zhou J; Tiemann K; Chomchan P; Alluin J; Swiderski P; Burnett J; Zhang X; Forman S; Chen R; Rossi J
Nucleic Acids Res; 2013 Apr; 41(7):4266-83. PubMed ID: 23470998
[TBL] [Abstract][Full Text] [Related]
17. Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection.
Thiel WH; Bair T; Peek AS; Liu X; Dassie J; Stockdale KR; Behlke MA; Miller FJ; Giangrande PH
PLoS One; 2012; 7(9):e43836. PubMed ID: 22962591
[TBL] [Abstract][Full Text] [Related]
18. Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas.
Sett A; Borthakur BB; Bora U
Clin Transl Oncol; 2017 Aug; 19(8):976-988. PubMed ID: 28224267
[TBL] [Abstract][Full Text] [Related]
19. Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy.
Mahlknecht G; Sela M; Yarden Y
Methods Mol Biol; 2015; 1317():3-15. PubMed ID: 26072398
[TBL] [Abstract][Full Text] [Related]
20. Aptamer-conjugated and doxorubicin-loaded grapefruit-derived nanovectors for targeted therapy against HER2
Tang Z; Jun Y; Lv Y; Li Y; Zhang Z; Tao M; Chen X; He J; Zhang L; Wang QL
J Drug Target; 2020 Feb; 28(2):186-194. PubMed ID: 31134823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
